GB2082176A - Heteroprostaglandin derivatives and processes for preparing them - Google Patents
Heteroprostaglandin derivatives and processes for preparing them Download PDFInfo
- Publication number
- GB2082176A GB2082176A GB8124488A GB8124488A GB2082176A GB 2082176 A GB2082176 A GB 2082176A GB 8124488 A GB8124488 A GB 8124488A GB 8124488 A GB8124488 A GB 8124488A GB 2082176 A GB2082176 A GB 2082176A
- Authority
- GB
- United Kingdom
- Prior art keywords
- hydroxy
- compound
- derivative
- acid
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 31
- 230000008569 process Effects 0.000 title claims description 10
- -1 alkali metal salts Chemical class 0.000 claims abstract description 25
- 239000001257 hydrogen Substances 0.000 claims abstract description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 15
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 claims abstract description 9
- 210000001772 blood platelet Anatomy 0.000 claims abstract description 8
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 120
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 93
- 239000002904 solvent Substances 0.000 claims description 50
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 238000002360 preparation method Methods 0.000 claims description 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- 239000012298 atmosphere Substances 0.000 claims description 7
- 229910010277 boron hydride Inorganic materials 0.000 claims description 7
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 6
- HCRWXCXWUZRCJE-KSZLIROESA-N (2R)-7-[(1S,2S)-2-heptoxycyclopentyl]-2-hydroxyheptanoic acid Chemical compound O[C@@H](C(=O)O)CCCCC[C@H]1CCC[C@@H]1OCCCCCCC HCRWXCXWUZRCJE-KSZLIROESA-N 0.000 claims description 6
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 6
- 229940035437 1,3-propanediol Drugs 0.000 claims description 6
- 239000007868 Raney catalyst Substances 0.000 claims description 6
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 6
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 6
- JUWYRPZTZSWLCY-UHFFFAOYSA-N 5-carboxypentyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCC(=O)O)C1=CC=CC=C1 JUWYRPZTZSWLCY-UHFFFAOYSA-N 0.000 claims description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 229960002523 mercuric chloride Drugs 0.000 claims description 5
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 claims description 5
- VCRYGHPVKURQMM-UHFFFAOYSA-N methane;platinum Chemical compound C.[Pt] VCRYGHPVKURQMM-UHFFFAOYSA-N 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- NCHPDGCQTUJYKK-UHFFFAOYSA-N pyrrolidin-1-ium;acetate Chemical compound CC(O)=O.C1CCNC1 NCHPDGCQTUJYKK-UHFFFAOYSA-N 0.000 claims description 5
- 238000007239 Wittig reaction Methods 0.000 claims description 4
- 229910000085 borane Inorganic materials 0.000 claims description 4
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- UMHJEEQLYBKSAN-UHFFFAOYSA-N Adipaldehyde Chemical class O=CCCCCC=O UMHJEEQLYBKSAN-UHFFFAOYSA-N 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims description 3
- RAIYODFGMLZUDF-UHFFFAOYSA-N piperidin-1-ium;acetate Chemical compound CC([O-])=O.C1CC[NH2+]CC1 RAIYODFGMLZUDF-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000007883 bronchodilation Effects 0.000 claims description 2
- 150000001940 cyclopentanes Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 125000002433 cyclopentenyl group Chemical class C1(=CCCC1)* 0.000 claims 9
- 150000003254 radicals Chemical class 0.000 claims 5
- 125000003172 aldehyde group Chemical group 0.000 claims 2
- 150000005840 aryl radicals Chemical class 0.000 claims 2
- 125000000468 ketone group Chemical group 0.000 claims 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- OHBTULDTCSOWOY-UHFFFAOYSA-N [C].C=C Chemical group [C].C=C OHBTULDTCSOWOY-UHFFFAOYSA-N 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 239000000168 bronchodilator agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 82
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 70
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 238000000921 elemental analysis Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 239000012429 reaction media Substances 0.000 description 21
- 238000004809 thin layer chromatography Methods 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 239000003208 petroleum Substances 0.000 description 20
- 229910052938 sodium sulfate Inorganic materials 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 239000012312 sodium hydride Substances 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 7
- 150000004678 hydrides Chemical class 0.000 description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000000010 aprotic solvent Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 150000002009 diols Chemical class 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 4
- 229960004484 carbachol Drugs 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000786363 Rhampholeon spectrum Species 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
- QLVKECUOHNDWOI-UHFFFAOYSA-N 2-oxo-1,3,2$l^{5}-diazaphosphonan-2-amine Chemical compound NP1(=O)NCCCCCCN1 QLVKECUOHNDWOI-UHFFFAOYSA-N 0.000 description 2
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 230000003182 bronchodilatating effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- 229940093476 ethylene glycol Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- PJJXSRBLNYZQDS-VAMGGRTRSA-N (1s,2r,3r)-2-heptoxy-3-phenylmethoxycyclopentane-1-carbaldehyde Chemical compound C1C[C@H](C=O)[C@@H](OCCCCCCC)[C@@H]1OCC1=CC=CC=C1 PJJXSRBLNYZQDS-VAMGGRTRSA-N 0.000 description 1
- XFUNLLJAVDIRSQ-HVWQDESWSA-N (1s,2r,3r)-3-phenylmethoxy-2-[(2s)-2-phenylmethoxyheptoxy]cyclopentane-1-carbaldehyde Chemical compound O([C@H]1[C@@H]([C@H](CC1)C=O)OC[C@H](CCCCC)OCC=1C=CC=CC=1)CC1=CC=CC=C1 XFUNLLJAVDIRSQ-HVWQDESWSA-N 0.000 description 1
- ZLAPGVQTWHCDPT-PIJUOVFKSA-N (2R)-2-phenylmethoxycyclopentan-1-ol Chemical compound C(C1=CC=CC=C1)O[C@H]1C(CCC1)O ZLAPGVQTWHCDPT-PIJUOVFKSA-N 0.000 description 1
- GCXZDAKFJKCPGK-ZETCQYMHSA-N (2s)-heptane-1,2-diol Chemical compound CCCCC[C@H](O)CO GCXZDAKFJKCPGK-ZETCQYMHSA-N 0.000 description 1
- YEBOTUWGKIGODZ-CYBMUJFWSA-N (3r)-3-phenylmethoxycyclopentene-1-carbaldehyde Chemical compound C1CC(C=O)=C[C@@H]1OCC1=CC=CC=C1 YEBOTUWGKIGODZ-CYBMUJFWSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- XXSWYMHVGAFXDY-AWEZNQCLSA-N (7r)-7-phenylmethoxy-1,4-dithiaspiro[4.4]non-8-ene-9-carbaldehyde Chemical compound C([C@H](C=C1C=O)OCC=2C=CC=CC=2)C11SCCS1 XXSWYMHVGAFXDY-AWEZNQCLSA-N 0.000 description 1
- XPIJMQVLTXAGME-UHFFFAOYSA-N 1,1-dimethoxycyclohexane Chemical compound COC1(OC)CCCCC1 XPIJMQVLTXAGME-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- NSMAFBHUMLLGKA-UHFFFAOYSA-N 1,4-dithiaspiro[4.4]non-8-ene-9-carbaldehyde Chemical class O=CC1=CCCC11SCCS1 NSMAFBHUMLLGKA-UHFFFAOYSA-N 0.000 description 1
- CWBCHVVTDJAGBP-UHFFFAOYSA-N 1,4-dithiaspiro[4.5]decane Chemical compound S1CCSC11CCCCC1 CWBCHVVTDJAGBP-UHFFFAOYSA-N 0.000 description 1
- BSVXBXNZZNYAIK-UHFFFAOYSA-L 2,2,2-triphenyl-1,3,2$l^{5}-dioxabismetan-4-one Chemical compound O1C(=O)O[Bi]1(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 BSVXBXNZZNYAIK-UHFFFAOYSA-L 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-O 2-carbamoyloxyethyl(trimethyl)azanium;hydron;chloride Chemical compound Cl.C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-O 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229910000545 Nickel–aluminium alloy Inorganic materials 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 239000000561 aggregant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001941 cyclopentenes Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000004252 dithioacetals Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 1
- AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000005092 tracheal tissue Anatomy 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
- C07C45/296—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with lead derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
- C07C45/66—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups by dehydration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/47—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/06—Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Prostanoic acid derivatives represented by the general formula: <IMAGE> in which X represents hydrogen or hydroxy, X1 represents hydrogen or X and X1, when they are taken together with the carbon atom to which they are attached, represent a carbonyl group and Z represents hydrogen or hydroxy and pharmaceutically acceptable alkali metal salts thereof, are disclosed as being of use as bronchodilators and/or inhibitors of blood-platelet aggregation.
Description
SPECIFICATION
Hetero-prostaglandin derivatives and processes for preparing them
This invention relates to prostaglandin derivatives and is concerned with novel compounds related in structure to prostanoic acid which has the structural formula:
and which, in accordance with common usage, can also be written as follows:
The present invention is also concerned with a process for preparing the said novel compounds.
The prostaglandin derivatives of the invention which are 13-oxa-prostaglandins, can be represented by the general formula:
in which X represents hydrogen or hydroxy, X1 represents hydrogen or X and X1 when they are taken together with the carbon atom to which they are attached represent a carbonyl group and Z represents hydrogen or hydroxy.
The invention also relates to the pharmacologically acceptable salts of the compounds of formula I such as, for example, the salts resulting from the action of the said compounds of formula I and an alkali metal hydroxide such as sodium hydroxide.
Another object of the invention is to provide novel chiral compounds. These compounds are particularly useful as intermediate compounds for preparing prostaglandin derivatives and especially the prostaglandin derivatives of formula I above.
The novel chiral compounds in question are cyclopentene derivatives which can be represented by the general formula
in which R represents a hydroxy-protecting group of the formula -CH2R1 in which R1 represents an aryl or aralkyl radical,
B represents
or
and A is such that: - when B represents
A represents
or
- when B represents
A represents
With respect to R1, suitable meanings for aryl can be, for instance, phenyl substituted or not buy a methyl radical and for aralkyl appropriate values can be, for example, benzyl substituted or not in the aromatic moiety by a methyl radical.
As a preferred value for R, benzyl can be cited.
Thus, preferred compounds covered by general formula la, are the following: 2-Formyl-4 (R)-benzyloxy-2-cyclopentenone-ethylenedithioacetal referred to hereinafter as "Synthon A".
2-Formylpropyleneacetal-4 (R)-benzyloxy-2-cyclopentenone-ethylenedithioacetal referred to hereinafter as "Synthon B".
2-Formyl propyleneacetal-4 (R)-benzyloxy-2-cyclopentenone referred to hereinafter as "Synthon C".
2-Formylpropyleneacetal-4 (R)-benzyloxy-2-cyclopentanol referred to hereinafter as "Synthon D".
1-Formyl-3 (R)-benzyloxy-1-cyclopentene referred to herainafter as "Synthon E".
1 -Formylpropyleneacetal-3 (R)-benzyloxy-l -cyclopentenone referred to hereinafter as "Synthon F".
Yet another object of the invention is concerned with a process for preparing the compounds of formula la.
The invention is also concerned with a method of using Synthons A two F as intermediate products for the preparation of the compounds of formula I above.
For the last fifteen years or so, prostaglandins have constituted a diversified and actively investigated research field. The chemical work that has been done in this field has resulted in the total synthesis of numerous prostaglandins and their analogs.
Since thromboxan (TXA2) and prostacyclin (pig12) were discovered with their physiological activities which oppose each other, a considerable amount of research work has been devoted to this type of compound.
Both substances are biosynthetized in living organisms from arachidonic acid via endoperoxide (PGH2).
Thromboxans are formed in human platelets and induce platelet aggregation, whereas prostacyclin, which is released from the vascular walls, inhibits such aggregation. Thus, theoretically, these two compounds regulate the formation of each other and failure or disturbance of this process of regulation causes the TXA2-PG12 balance to be upset which inturn leads to cardiovascular diseases such as thrombosis, infarction and the like.
Prostanoic acid derivatives having a 13-heteroatom and endowed with an inhibitory action on platelet aggragation have already been described in British Patent Application No. 2,028,805 A and in J. Med. Chem.
vol.22, No.11 pp.1402-1408(1979).
In British Patent Application No. 2,028,805 A the heteroatom is nitrogen while in the J. Med. Chem.
reference in question the heteroatom is oxygen, a two-nitrogen bridge being fixed between the 9- and 11-positions giving rise to a 9,11-azo derivative.
It has now been found that a new series of prostanoic acid derivatives, namely 1 1-hydroxy-prostanoic acid derivatives, in which the carbon atom in the 13-position has been replaced by an oxygen atom, presents pharmacological properties generally found in the prostaglandin series, more particularly an inhibitory effect on blood-platelet aggregation and/or a bronchodilating action.
In view of their pharmacological properties, the 1 3-oxa-prostaglandin derivatives of the invention are capable of being used therapeutically in the treatment of pathological states which affect the respiratory system, and especially asthma. Furthermore, these compounds can be used as antithrombotic agents and in the treatment and prevention of cardiovascular diseases or pathological conditions such as myocardial infarction.
Therefore, another object of the invention relates to a method of provoking bronchodilation or inducing inhibition of blood-platelet aggregation in a host needing such treatment, method which comprises administering to said host an effective amount of at least one 1 3-oxa-prostag landin of the invention.
For human thereapy the compounds of the invention will be used at daily dosages of 0.1 to 40 mg/kg by oral route and of 0.3 to 120 mg by aerosol administration.
Yet another object of the present invention is to provide pharmaceutical and veterinary compositions comprising as an essential active ingredient at least one oxaprostaglandin of formula I or a pharmaceutically acceptable salt thereof, in association with a pharmaceutical carrier or excipient therefor.
All the compounds of the invention can be obtained from Synthons A to F. The process for preparing these
Synthons A to F comprises a number of original steps starting from (3R, 4S, 5R)-3,4-0-cyclohexylidene-3,4,5- trihydroxy-cyclohexanone, this latter compound being obtained from quinic acid, as described, for instance, by CLEOPHAX, LEBOUL, GERO, AKHTAR, BARNETT, PEARCE in J.A.C.S., 1976,98,7110.
The process of the invention for the preparation of the chiral intermediate compounds in question as well as for the preparation of the 1 3-oxa-prostaglandins of the invention can be summarized as follows:
A. Preparation of Synthon A a) Reaction of (3R,4S,5R)-3,4-O-cyclohexylidene,3,4,5-trihydrnxy-cyclohexanone of formula::
in the presence of boron trifluoride etherate, with ethanedithiol at room-temperature and in an aprotic solvent such as, for example, benzene, toluene, chloroform or dichloromethane, to provide (3R, 4S, 5R)-3,4,5-trihydroxy-cyclohexanone-ethylenedithioacetal of formula
b) Treatment of the dithioacetal III with 1,1 ,-dimethoxycyclohexane in the presence of an acid catalyst such
as, for example, sulphuric acid or p-toluenesulphonic acid, at room-temperature and in an aprotic solvent,
for instance, N,N-dimethylformamide, to obtain (3R, 4S, 5R)-3,4,0-cyclohexylidene-3,4,5-trihydro cyclohexanone-ethylenedithioacetal formula : of formula:
c) Protection of the free hydroxy group of compound IV with a bromide of the formula R Br in which R has the
same meaning as above, preferably benzyl, in the presence of an alkali metal hydride, for instance sodium
hydride, preferably at 0 C and in an aprotic solvent such as, for instance, N,N-dimethylformamide,
dimethylsulfoxide or hexamethylenephosphoramide to provide (3R, 4S, 5R)-3,4,0-cyclohexylidene-3,4,5- trihydroxy-cyclohexanone-ethylenedithioacetal derivatives of general formula:
in which R1 has the same meaning as above and which can be used either isolated or not in the following
step: d) Treatment of the ether V with a strong inorganic acid, for instance hydrochloric acid, in an alcohol, for
instance methanol, ethanol or isopropanol, and at the reflux temperature of the medium, to provide (3R,
4S,5R)-3,4,5-trihydroxy-cyciohexanone-ethylenedithioacetal derivatives of general formula:
in which R1 has the same meaning as above.
e) Oxidation of the diol VI by means of neutral lead tetraacetate ortriphenylbismuth carbonate in an
appropriate solvent, for example, toluene, and at room-temperature, to obtain 4-oxo-ethylenedithioacetal
hexanedial derivatives of general formula:
in which R1 has the same meaning as above.
f) Cyclisation of the acyclic dialdehyde VII in situ and under inert atmosphere with pyrrolidine acetate or
piperidine acetate in an appropriate solvent, such as benzene ortoluene, and at a temperature ranging
from -10"C to room-temperature, preferably at 00C, to obtain 2-formyl-2-cyclopentenone
ethylenedithioacetal derivatives of general formula:
in which R, has the same meaning as given above or Synthon A.
B. Preparation ofSynthon B
Synthon A hereabove is treated with 1,3-propanediol at room-temperature and in the presence of p-toluenesulfonic acid, the treatment being carried out in an anhydrous solvent, for example benzene or toluene, which provides 2-formylpropyleneacetal-2-cyclopentenone-ethylenedithioacetal derivatives of general formula:
in which R, has the same meaning as given above or Synthon B.
C. Preparation of Synthon C
Synthon B is treated with neutral diphenylselenic anhydride at room-temperature and in an appropriate solvent, for instance dichloromethane, to provide 2-formylpropyleneacetal-2-cyclopentenone derivatives of general formula
in which R, has the same meaning as given above or Synthon C.
D. Preparation of Synthon D
Synthon C is treated with diisobutyl aluminium hydride in an appropriate anhydrous solvent, for instance benzene or toluene, and at a temperature ranging from -10"C to room-temperature preferably at 0'C to obtain 24ormylpropyleneacetal-2-cyclopentenol derivatives of general formula:
in which R1 has the same meaning as given above or Synthon D.
E. Preparation of Synthon E a) Treatment of diols VI above under reflux with Raney nickel (catalyst of finely divided nickel obtained by
dissolving out with alkali the aluminium from a nickel-aluminium alloy) in an appropriate solvent, for
instance ethanol, to provide (1R, 2S, 3R)-1 ,2,3-trihydroxy-cyclohexane derivatives of general formula
in which R1 has the same meaning as given above.
b) Oxidation of diols XII by means of neutral lead tetraacetate or triphenylbismuth carbonate in an
appropriate anhydrous solvent, for example chloroform, and at room-temperature to obtain hexanedial
derivatives of general formula:
in which R1 has the same meaning as given above.
c) Cyclisation of the acyclic dialdehydes XIII in situ and under inert atmosphere with pyrrolidine acetate or
piperidine acetate in an appropriate solvent, such as toluene, and at a temperature ranging from -1 00C to room-temperature, preferably at 0 C, to obtain l-formyl-l -cyclopentene derivatives of general formula:
in which R1 has the same meaning as given above or Synthon E.
F. Preparation ofSynthon F
Synthon E hereabove is treated with 1,3-propanediol at a temperature between room-temperature and 40"C, for instance at 300C, and in the presence of p-toluenesulfonic acid, the treatment being carried out in an anhydrous solvent, for example benzene ortoluene, which provides 1 -formylpropyleneacetal-1 - cyclopentenone derivatives of general formula:
in which R1 has the same meaning as given above or Synthon F.
G. Preparation of the 13-oxa-prostaglandins of formula I
Synthon B or Synthon F is first treated with boron hydride in tetrahydrofuran at a temperature ranging from 0 C to room-temperature and the borane so formed is oxidized with hydrogen peroxide in the presence of sodium hydroxide, at a temperature ranging from 0 C to room-temperature, to obtain cyclopentane derivatives of general formula:
in which D represents
and R1 has the same meaning as given above.
Different procedures are then applied to compounds XVI in accordance with the chemical structure of the 13-oxa-prostaglandin of formula I to be obtained.
1. When X andXr taken together with the carbon atom to which they are attached represent a carbonyl group and represents hydrogen or hydroxy.
a) Treatment of compounds XVI in which D represents
in the presence of an alkali metal hydride, for instance sodium hydride, at room-temperature and in an appropriate solvent, for example N,N-dimethylformamide, with a 1-halogeno-n-heptane derivative of general formula :
in which Hal represents chlorine, bromine or iodine, and Z' represents hydrogen or a protected hydroxyl group of the formula OR in which R has the same value as given above, thus providing 2(S) formylpropyleneacetal-3(R)-heptyloxy derivatives of general formula:
in which Z' and R1 has the same meaning as given above.
b) Hydrolysis of compounds XVIII in the presence of trifluoroacetic acid in chloroform or hydrochloric acid in
anhydrous chloroform/isopropanol, under inert atmosphere, to obtain 2(S)-formyl-3(R)-heptyloxy derivatives of general formula
in which Z' and R1 have the same meaning as given above.
c) Treatment of compounds XIX under inert atmosphere, with the dianion of (5-carboxypentyl)
triphenylphosphonium bromide at room-temperature and in an appropriate anhydrous solvent such as,
for instance, ethyl ether, in accordance with the conditions of the Wittig reaction, to obtain 2(S)-(6-carboxy-1 -hexenyl)-3(R)-heptyloxy derivatives of general formula:
in which Z' and R1 have the same meaning as given above.
d) Deprotection of the hydroxyl groups of compounds XX by hydrogenolysis on platinum charcoal or
palladium charcoal at room-temperature and in an appropriate medium, for instance an acetic
acid/ethanol medium, to obtain 2(S)-(6-carboxyhexyl)-3(R)-heptyloxy derivatives of general formula:
in which Z has the same meaning as in formula I.
e) Dethioacetalisation of compounds XXI with mercuric chloride in an appropriate solvent, such as acetone,
and in the presence of boron trifluoride etherate to give 2(S)-(6-carboxyhexyl)-3(R)-heptyloxy derivatives
of general formula:
wherein Z has the same meaning as in formula I, which are the desired 13-oxa-prostaglandins of formula
II. When Xand Xt each are hydrogen andzrepresents hydrogen orhydroxy.
a) Treatment of compounds XVI with a n-halogenoheptane derivative as described in para G la) hereaboveto obtain: - when D represents
2(R)-heptyloxy-cyclopentane derivatives of general formula:
in which Z' and R1 have the same meaning as given above. - when D represents
the compounds of formula XVIII above which, after reduction under reflux and on Raney nickel, provide a mixture of non-isolated products of general formula:
in which Z' and R1 have the same meaning as given above, this mixture being further hydrogenated at
atmospheric pressure on Adams platinum (catalyst of platinum oxide prepared from chloroplatinic acid)
to give the compounds of formula XXII above.
b) Hydrolysis of compounds XXII in the presence of an appropriate acid, for example trifluoroacetic acid or
formic acid to give 2(R)-heptyloxy derivatives of general formula:
in which Z' and R1 have the same meaning as given above.
c) Treatment of compounds XXIII, under inert atmosphere, with the dianion of (5-carboxypentyl)
triphenylphosphonium bromide at room-temperature and in an appropriate anhydrous solvent, for
instance ethyl ether or dimethylsulfoxide, in accordance with the conditions of the Wittig reaction to
obtain 1 (S)-(6-carboxy-1 -hexenyl)-2(R)-heptyloxy derivatives of general formula:
in which Z' and R1 have the same meaning as given above.
d) Deprotection of the hydroxyl groups of compounds XXIV by hydrogenolysis on platinum charcoal or
palladium charcoal at room-temperature and in an appropriate medium, for instance an acetic acid/ethanol medium, to obtain 1(S)-(8carboxyhexyl 1 (S)-(6-carboxyhexyl)-2(R)-heptyloxy derivatives of general formula:
wherein Z has the same meaning as in formula I, which are the desired 13-oxa-prostaglandins of formula III. When Xrepresents hydroxy, XI represents hydrogen and Zrepresents hydrogen orhydroxy.
These compounds can be obtained starting from 2(S)-formylpropyleneacetal-3(R)-heptyloxy-cyclopentane derivatives of general formula:
in which Z' and R1 have the same meaning as given above, these compounds being obtained in accordance with the following steps which comprise: either a) Treatment of compounds XVI, in which D represents
with a n-halogenoheptane as described in para Gla) hereabove to obtain compounds XVIII.
b) Dethioacetalisation of compounds XVIII with mercuric chloride in an appropriate solvent, such as acetone,
and in the presence of boron trifluoride etherate to give 1-oxo-3(R)-heptyloxy derivatives of general formula:
in which Z' and R1 have the same meaning as given above.
c) Reduction of the ketonic function using lithium tri-sec-butylborohydride as catalyst to give 3(R)-heptyloxy
cyclopentanol derivatives of general formula:
in which Z' and R1 have the same meaning as given above.
d) Protection of the free hydroxyl group of compounds XXVII with a bromide of the formula R Br in which R
has the same meaning as above, preferably benzyl, in the presence of sodium hydride and in an
appropriate aprotic solvent to give the 3(R)-heptyloxy-cyclopentane derivatives which correspond to the
compounds of general formula XXV.
or a) Protection of the free hydroxyl group of Synthon D with a bromide of the formula R Br in which R has the
same meaning as above, preferably benzyl, in the presence of an alkali metal hydride, for instance sodium
hydride, preferably at 0OC and in an aprotic solvent such as, for instance, N,N-dimethylformamide, dimethylsulfoxide or hexamethylenephosphoramide, to provide 2-formylpropyleneacetal-2-cyclopentene derivatives of general formula
in which R1 has the same meaning as given above.
b) Treatment of compounds XXVIII with boron hydride as described in para G) hereabove to obtain
2(S)-formylpropyleneacetal-3(R)-hydroxy-cyclopentane derivatives of general formula:
in which R1 has the same meaning as given above.
c) Treatment of compounds XXIX with a n-halogenoheptane derivative as described in para Gla) hereabove
to obtain 2(S)-formylpropyleneacetal-cyclopentane derivatives which correspond to the compounds of
general formula XXV.
The compounds XXV above are then submitted to the following reactions.
a) Hydrolysis in the presence of an appropriate acid, for example trifluoroacetic acid, to obtain
2(S)-formyl-cyclopentane derivatives of general formula:
in which Z' and R1 have the same meaning as given above.
b) Treatment of compounds XXX under inert atmosphere with the dianion of (5-carboxypentyl)
triphenylphosphonium bromide at room-temperature and in an appropriate anhydrous solvent such as,
for instance, ethyl ether in accordance with the conditions of the Wittig reaction to obtain 2(S)-(6-carboxy 1-hexenyl)-cyclopentane derivatives of general formula
in which Z' and R1 have the same meaning as given above.
c) Deprotection of the hydroxyl groups of compounds XXXI by hydrogenolysis on platinum charcoal or palladium charcoal at room-temperature and in an appropriate medium, for instance an acetic acid/ethanol medium, to obtain 2(S)-(6-carboxyhexyl)-3(R)-heptyloxy derivatives of general formula:
wherein Z represents hydrogen or hydroxy which are the desired 13-oxa-prostaglandins of formula I.
With respect to the pharmaceutically acceptable salts of the heteroprostaglandins of formula I, these will be obtained, in a classical manner, by reacting the acid of formula I with an appropriate alkali metal hydroxide, for instance, sodium hydroxide.
As regards the halogenoheptane derivatives of formula XVII in which Z' represents an -OR group, these can be obtained from (S)-(-)heptane-1,2-diol described by K. MORI in Agr. Biol. Chem. 40, 1617 (1976).
This diol is tritylated to obtain the 1-0-trityl derivative and the 2-hydroxy is then protected using a bromide of the formula R Br in which R has the meaning given above, preferably benzyl.
The 1-0-trityl is then deprotected and the free hydroxyl so regenerated is substituted by a halogen atom using conventional procedures so as to provide the compounds of formula XVII in which Z' represents the -OR group in question.
Tests were carried out in order to evaluate the pharmacological properties of the 1 3-oxa-prostaglandins of the invention.
Bronchodilatory action
This action was determined by verifying the relaxant action on the isolated guinea-pig trachea previously contracted with carbachol i.e. carbamoylcholin hydrochloride.
For this purpose, spiral strips of about 3 mm in width of the tracheal tissue were maintained in a survival medium. The isometric tension of the guinea-pig tracheal preparations was continuously registered. An initial tension of 8 g was applied to each preparation. After a rest period of 60 minutes, a submaximal contraction was obtained by adding carbachol to the bath. When the contractile response of the preparation became reproducible 11 (R)-hydroxy-1 3-oxa-prnstanoic acid of formula I was added to the bath either when the carbachol-induced contraction was at its maximum so as to appreciate its relaxant action or when the preparation was completely relaxed so as to evaluate the influence of the acid on the basal tonus.
Under these conditions, 11 (R)-hydroxy-1 3-oxa-prostanoic acid provoked a moderate decrease of the basal tonus of the guinea-pig tracheal preparation.
The amplitude of this decrease depended on the dose employed of the prostanoic acid derivative.
Furthermore, the relaxant action at concentrations of about 10-5 and about 4.10-5 mol of 11 (R)-hydroxy13-oxa-prostanoic acid on preparations contracted by 8.10-8 mol of carbachol was also found to be moderate.
In addition, it was found that the relaxant effect in question was not similar to a ss2-adrenoreceptor stimulant effect since in the presence of 105 mol of propranolol, the relaxant effect was not modified in either trial.
Inhibitory action on platelet aggregation
This test was performed in vitro on citrated human plasma using thrombine as aggregant agent.
Aggregation was carried out after incubation of the fraction of plasma rich in platelets for 20 min. at room-temperature in the presence of 5 ll1 of 11(R)-hydroxy-13-oxa-prostanoic acid of the invention in dimethylsulphoxide at a concentration of 1 mg/ml. The controls were incubated in a similar manner with 5 I of dimethylsulphoxide.
The samples to be used for titration of thromboxane B2 were taken after 3 min. aggregation using 0.4 U/ml of thrombine and in the presence of 100 Rg/ml of indomethacine and 100 pg/ml of imidazole (1001l1 per 400 ,tl of fraction rich in platelets).
The thromboxane B2 was then determined.
In this test, the amounts of thromboxane B2 found were 857 ng/ml when the studied compound was present.
This thus shows that when the oxaprostaglandin of the invention was used there was a 77%-decrease in thromboxane B2 and a 47%-inhibition of platelet aggregation.
The therapeutic compositions of the invention can be made up in any form which is suitable for their administration in human and veterinary therapy. For ease of administration, the composition will normally be made up in a dosage unit form appropriate to the desired mode of administration, for example, a compressed tablet for perlingual administration, a pill, a powder, a capsule, a syrup, an emulsion for oral administration, a suspension for oral or aerosol administration, a suppository for rectal administration or a sterile solution or suspension for parenteral administration.
The therapeutic compositions in question will be prepared in accordance with known techniques by associating at least one compound of the invention with an appropriate diluent or excipient and then, if required, making up the resulting admixture in the desired dosage unit form.
Examples of suitable diluents and excipients are distilled water, ethanol, talc, magnesium stearate, starches, sugars and cocoa butter.
The preparation of compounds of the invention is illustrate by the following Examples.
EXAMPLE 1 Preparation of yI-4(R)-benzyloxy-2-cyclopentenone-ethylenedfthioacetal or Synthon A (compound VIII with R1= phenyl) a) (3R, 4S, 5R)-3,4,5-trihydroxy-cyclohexanone-ethylenedithioacetal (compound lil) To 89 of (3R,4S,5R)-3,4-0-cyclohexylidene-3,4,5-trihydroxy-cyclohexanone (compound II) dissolved in 40 ml of anhydrous chloroform, 16 ml of ethanedithiol and 1.6 ml of freshly distilled boron trifluoride etherate were added. After one hour at room-temperature, thin layer chromatography was performed (solvent: 3/1 chloroform/ethyl ether) and the starting compound was found to have disappeared.The desired compound lil precipitated as it was formed in the reaction medium and was then dissolved by adding methanol. The solution was neutralized with sodium bicarbonate, filtered and the solvents were evaporated off. The resulting solid was dissolved again in hot acetone and the insoluble salts were then filtered.
In this manner, compound Ill was obtained after crystallization from acetone.
Yield: 95%
M.P.: 129-130"C aD: -41" (methanol, C=1.4%WN) b) (3R, 4S, 5RJ-3,4-0-cyclohexylidene-3,4,5-trih ydroxy-cyclohexanone-eth ylenedithioacetal (compound lVJ To 79 of the previously obtained compound III, dissolved in 30 ml of N,N-dimethylformamide, were added 8 ml of 1,1-dimethoxycyclohexane and 0.5 ml of concentrated sulphuric acid. Th methanol formed in the reaction was evaporated off from time to time using a water pump so as to facilitate a shift in equilibrium leading to the desired compound IV.The reaction was terminated after two days at room-temperature as determined by thin layer chromatography (solvent: 3/1 chloroform/ethyl ether). The solution was diluted with dichloromethane and neutralized with sodium bicarbonate. After filtration, the organic phase was washed with water and then dried on sodium sulphate and concentrated under reduced pressure.
In this manner, compound IV was obtained after crystallization from petroleum ether.
Yield: 95%
M.P.: 138-140"C aD: -44" (chloroform, C=1.02% WN) 13 C N.M.R.
N"C 1 2 3 4 5 6 7 8 b(ppm) 62.97 46.46 73.76 79.67 71.55 41.59 40.16 25.02 N"C 9 10 11 12 13 14 5 (ppm) 23.72 24.04 35.35 110.09 38.01 38.21 c) (3R, 4S, 5R-3,4-0-cyclohexylidene-5-0-benzyl-3,4 5-trihydroxy-cyclohexan one-eth ylenedithioacetal (com
pound Vwith R1= phenyl)
Into a three-necked flask were introduced 0.845 g of sodium hydride and 47 ml of N,N-dimethylformamide under nitrogen at 0 C. After that, 9 g of compound IV were added followed by 3.6 ml (1.3 equivalent) of benzyl bromide once the solid was dissolved. The reaction medium showed a orange-yellow colour.The reaction was terminated after three hours as determined by thin layer chromatography (solvent : 3/1 chloroform/ethyl ether). The hydride in excess was removed by adding methanol and the reaction mixture was first poured into iced water and then extracted with dichloromethane. The organic phase was washed with water and dried on sodium sulphate. Evaporation of the solvents gave a yellow oil.
In this manner, the required compound V was obtained after crystallization from aqueous ethanol.
Yield: 95%
M.P.: 68-69"C aD: -50" (chloroform, C=1.06% WN) Elemental analysis
C21 H28 O3 S2 Mol. Wt. : 392.587
calculated C :64.25 H :7.19 S:16.34 found (%) C :64.15 H :6.96 S:16.52 d) (3R, 4S, 5R)-5-0-benzyl-3,4,5-trihydroxy-cyclohexanone-ethylenedithioacetal (compound Vl with RI= phenyl)
The following reaction was effected directly from the raw compound V (yellow oil) obtained previously.
In 120 ml of methanol were dissolved 12 g of raw compound V. After that, 10 ml of 12 N-hydrochloric acid were added and the medium was heated to 70"C.
When the hydrolysis was complete, as determined by thin layer chromatography (solvent : 3/1 chloroform/ethyl ether), the reaction medium was diluted with dichloromethane and neutralized with sodium bicarbonate. The solution was then filtered and evaporated. The residue was taken up in dichloromethane and the organic phase was washed with water, dried on sodium sulphate, filtered and evaporated.
In this manner, the required compound VI was obtained after crystallization from ethanol or ethyl acetate.
Yield: 88%
M.P.: 135-136"C αD,:-72 (chloroform, C=1.03% WN) Elemental analysis
C15 H20 03 S2 Mol. Wt. 312.457
calculated (%) C: 57.66 H : 6.45 S : 20.53 found (%) C :57.65 H : 6.53 S : 20.23 13CN.M.R. {d5pyridine) N"C 1 2 3 4 5 6 7 8 9 6 (ppm) 65.4 40.2 69.2 72.3 79.3 46.4 38.2 39.5 71.4 e) 2fRJ-benzyloxy-4-oxoethylenedithioacetal-hexanedial (compound Viz in which R1 = phenyl)
In a coloured flask, 1.33 g (3 mM) of lead tetraacetate was dried using a vane pump so as to remove all traces of acetic acid.After this operation, 100 ml of anhydrous toluene and 0.624 g (2 mM) of compound VI previously obtained were added. The reaction medium was then stirred at room-temperature.
After an hour and a half, the reaction was terminated as determined by thin layer chromatography (solvent : 3/1 chloroform/ethyl ether) and 3 ml of ethylene glycol were then added to remove the lead tetraacetate in excess. When this excess has reacted, the solution became clear. The reaction medium was then diluted with dichloromethane and the organic phase was washed once with water, then with a saturated solution of sodium bicarbonate and finally with water to neutrality. The organic phase was then dried on sodium sulphate, filtered and evaporated.
In this manner, the required compound VII was obtained in a quantitative yield in the form of a colourless oil which acquired a yellow tint in the course of time and had therefore be used without delay.
a0: -11(chIornform,C=2.4%W/V) As this compound is a particularly unstable product, it was reduced for characterization purposes thus giving 2(R)-benzyloxy-4-oxoethylenedithioacetal-hexanediol.
Elemental analysis of this diol
C15 H22 03 S2. Mol. Wt. : 314.473
Calculated (%) C: 57.29 H : 7.05 S : 20.39 found (%) C :57.03 H :6.47 S : 20.18 a0: -20" (chloroform, C=1.4% WN f) 2-Formyl-4fR)-benzyloxy-2-cyclopentenone-ethylenedithioacetal (compound Vlil in which Tri= phenyl) In 20 ml of an hydros toluene, 0.620 g of the raw compound VII previously obtained was dissolved under nitrogen at 0 C. After that, 0.5 ml of a 1 N-solution of pyrrolidine acetate in anhydrous benzene was added.
The reaction medium was allowed to stand for 18 hours at OOC under nitrogen. At the end of this reaction time, thin layer chromatography (solvent : 3/1 chloroform/ethyl ether) showed that the starting compound had completely disappeared. The reaction medium was then diluted with dichloromethane and the organic phase was washed with water to neutrality, dried on sodium sulphate, filtered and evaporated.
In this manner, the required compound VIII or Synthon Awas obtained in the form of a pale yellow oil which was stored at 0 C in a coloured flask.
Yield: 95% N.M.R. of the proton at 60 MHz
6 (ppm) H
2.7 2H5 (A-B system octuplet)
3.45 2H7 + 2H7, (multiplet)
4.4 CH2 (phenyl) (singlet)
4.7 H4 (sextuplet)
6.65 H3 (doublet)
7.2 phenyl
9.5 H5 (singlet) I.R. (CHO3) 1685-1705 cm-' unsaturated a,gaidehyde M.S. (electron impact) M+= 292(201,186,91,77,65) EXAMPLE 2
Preparation of2-formylpropyleneacetal-4(R)-benzyloxy-2-cyclopentenone-ethylenedithioacetal or Synthon
B (compound IX in which RZ = phenyl)
The reaction was carried out directly from the previously obtained unsaturated a,ss-aldehyde.
In 50 ml of dry toluene, 0.550 g of compound VIII obtained in Example 1 fwas dissolved and 1.5 ml of 1,3-propanediol together with a trace of p-toluenesulphonic acid were then added. At the end of a 24-hour reaction time, 3/4 of the volume was evaporated off using a rotatory evaporator. After that, 1.5 ml of 1 ,3-propanediol and 50 ml of anhydrous toluene were added to shift the equilibirium in favour of the desired compound. This operation was carried out again 24 hours later. The reaction was almost terminated after 72 hours as determined by thin layer chromatography (solvent: 3/7 ethyl acetate/petroleum ether). However, there was still some of the starting aldehyde (5 to 10%) left. The reaction medium was diluted with dichloromethane, and neutralized with sodium bicarbonate.After filtering the salts, the organic phase was washed with water, dried on sodium sulphate, filtered and evaporated. The compound so obtained was then separated by thin layer chromatography (solvent: 3/7 ethyl acetate/petroleum ether). After the strip with the lower Rf value had been eluted with ethyl acetate and the solvents had been filtered and evaporated off, a colourless oil was obtained.
In this manner, the required compound IX or Synthon B was obtained after crystallization from petroleum ether.
Yield: 80%
M.P.: 70-71 C a0: + 86 (chloroform, C=1.12% WN) 13C N.M. R. (d5 pyridine) N"C 1 2 3 4 5 6 6' 7 8 8' 9 10 6 (ppm) (*) 146.3 131.6 80.3 53.8 41.3 40.5 97.3 67.3 67.3 25.8 70.9 (*) not identified on the spectrum (quaternary carbon)
Elemental analysis
C18 H22 03 S2 Mol.Wt. : 350.506 calculated (%) C :61.68 H :6.32 S :18.29 found (%) C :61.44 H : 6.28 S:18.37 N.M.R. of the proton at250 250MHz (CHcl3) 6 (ppm) H
7.34 phenyl
6.34 H3 J (H3-H4) = 2Hz
5.25 H7
4.65 H4
4.55 CH2 (phenyl)
4.22 H8a + H8ta 3.9 H80 + H8we 3.4 2H6 + 2H6 2.95 H5b (J(H5b-H5a) = 13.5 Hz
(J(H5b-H4 )= 6.5 Hz
2.6 H5a (J(H5b - H5a) = 13.5 Hz (J(H50-H4 )= 5 Hz
2.22 H9a
1.4 H90 EXAMPLE 3
Preparation of2-formylprop yleneacetal-4(R)-benzyloxy-2-cyclopentenone or Syn thon C (compound X in which R1 = phenyl)
To 0.180 g of compound IX obtained in Example 2 dissolved in 5 ml of anhydrous dichloromethane was added 0.203 9 (1.1 equivalent) of diphenylselenic anhydride (Ph2Se203) free from any trace of nitric acid.
After that, one drop of propylene oxide per 50 mg of starting compound was added so as to remove likely nitric acid remnants. At the end of a 20-hour reaction time, thin layer chromatography (solvent : 3/7 ethyl acetate/petroleum ether) showed that the starting compound had disappeared and that a compound with a lower Rf value had been formed.
The reaction medium was slightly diluted with dichloromethane, neutralized with sodium bicarbonate, filtered and separated by thin layer chromatography (solvent : 3/7 ethyl acetate/petroleum ether). The strip with the lower Rf value under U.V. light was eluted with ethyl acetate, filtered and the solvent was evaporated off.
In this manner, the required X or Synthon C was obtained in the form of a colourless oil cristallizing from petroleum ether.
Yield: 68%
M.P.: 42-43"C [a]D = + 42" (chloroform, C = 1WN)
Elemental analysis
C16 H18 04 Mol. Wt. : 274.316
Calculated (%) C: 70.05 H : 6.61 found (%) C:70.14 H:6.60 N. M.R. of the proton at 250MHz (CHCI3) 6 (ppm) H
7.7 H3
7.3 phenyl
5.3 H6
4.7 H4
4.6 CH2 (phenyl)
4.18 H7a + H7ta 3.9 H7e + H7te 2.75 H5b (J(HSb- H5a)= 18.5 Hz (J(H5b-H4 )= 6 Hz
2.43 H5a (J(HSb- H5a)= 18.5 Hz ( J (H5a - H4 ) = 2.5 Hz
2.15 H8a
1.35 H89 EXAMPLE 4
Preparation of2-formylpropyleneacetal-4(R)-benzyloxy-2-cyclopentenol or Synthon D (Compound XI in which RI = phenyl)
To 2.44 g of compound X obtained in Example 3 dissolved in 53 ml of anhydrous toluene, there were added, drop-by-drop, under nitrogen atmosphere and at 0 C, 13.1 ml of diisobutyl aluminium hydride (1 M commercial solution in hexane).
Thirty minutes later, thin layer chromatography (solvent: 3/1 chloroform/ethyl ether) showed that all the starting product has disappeared. The reaction was stopped by slowly adding methanol at 0 C. The solution was then poured into iced water saturated with sodium chloride and then taken up in dichloromethane. The organic fraction was dried on sodium sulphate and then evaporated to dryness. The oil so obtained was dissolved in a 3/1 mixture of chloroform/ethyl ether and this solution was first filtered on Celite (a commercially available diatomaceous silica product, the word "Celite" being a registered Trade Mark) and then evaporated to dryness. The desired product was crystallized from a dichloromethane/petroleum ether mixture. The mother-liquors showed in N.M.R. of the proton, the presence of another product which was the other isomer.
In this manner, the required compound XI or Synthon D was obtained.
Yield: 89% M.P.: 88-90 C Elemental analysis
C16 H20 04 Mol. Wt. : 276.336 calculated (%) C :69.54 H 7.29 found (%) C:69.36 H :7.30
MS.
= = 276.
EXAMPLE 5
Preparation of '-formyl-3(R)-benzyloxy-1-cyclopentene orSynthon E (compoundXlVin which R1 = phenyl) a) (iR, 2S, 3R)-3-0-benzyl- 1,2,3-trihydroxy-cyclohexane Rcompound Xll in which R1 = phenyl)
In 80 ml of 95 -ethanol was dissolved 1.3 g of compound VI obtained in Example 1 d. When the product was completely dissolved, Raney nickel was added in considerable excess and the medium was refluxed for 12 hours. The reaction mixture was filtered on Celite and thoroughly rinsed with ethanol so as to eliminate all the Raney nickel. The oil so obtained was taken up in chloroform and filtered on Whatmann paper. The required compound crystallized from petroleum ether.
In this manner, the required compound XII was obtained in a yield of 70%.
M.P.: 59-60"C (petroleum ether) a0 = -83" (chloroform, C = 1.3 WN)
Elemental analysis C13 H18 03 Mol. Wt. : 222.287 calculated (%) C :70.24 H :8.16 found (%) C:70.12 H:8.11 MS.
= = 222 b) 2(R)-benzyloxy-hexanedial (compoundXIIlin which R1 = phenyl)
In 120 ml of anhydrous chlorofrom were dissolved 2.34 g of compound XII previously obtained and 5.7 g of lead tetraacetate were added by small actions. The reaction was carried out protected from light and followed by thin layer chromatography (solvent: ethyl acetate/petroleum ether). Ninety minutes later, the
reaction terminated and ethyleneglycol was added to eliminate the lead tetraacetate in excess. When the solution was clear, it was taken up in dichloromethane washed with water, with sodium bicarbonate and again with water. The chloroform phase was dried on sodium sulphate and evaporated to dryness.
In this manner, the required compound XIII was obtained and directly reacted in the following step.
N.M.R. of the 2 aldehyde protons at 60 MHz : 9.6 ppm IF. spectrum : CHO at 1720 cam~1.
c) l-Formyl-3(R)-benzyloxy-1-cyclopentene (compoundXlVin which R7 = phenyl
Compound XIII previously obtained was dissolved in 100 ml of dry toluene and reacted, under nitrogen atmosphere and at 0 C, with 1 ml of a 2 N benzene solution of pyrrolidine acetate. The reaction medium was allowed to stand for about 8 hours at 0 C and then poured into iced water. After being taken up in dichloromethane, the organic phase was dried on sodium sulphate and concentrated under reduced
pressure. The a,-unsaturated aldehyde so obtained, in the form of a clear yellow oil, was relatively unstable and was directly used, without purification in the following step.
In this manner the required compound XIV or Synthon E was obtained.
N.M.R. at 60 MHz: 6 (ppm) H
9.8 aldehyde
7.3 phenyl
6.8 = CH l.R. spectrum : CHO a,ss unsaturated:1680 cm2-1 to 1710 cm-l EXAMPLE 6
Preparation of 1-Iormylprnpyleneacetal-3(R)-benzyioxy-1 cyclopentenone or Synthon F (compoundXVin which R = phenyl)
To compound XIII obtained in Example 5b dissolved in 100 ml of dry toluene, there were added 10 ml of 1,3-propanediol and a trace of p-toluenesulphonic acid. The mixture was stirred at 30"C with a rotatory evaporator for one hour and then kept under stirring for a further 24 hours.When the reaction was terminated, the reaction medium was diluted with dichloromethane and neutralized with sodium bicarbonate.
After 30 minutes of stirring at room-temperature, the solution was filtered and extracted with dichloromethane. After being washed with water, the organic phase was dried on sodium sulphate and evaporated under reduced pressure to obtain a dark oil which was purified by thin layer chromatography (solvent 1/2 ethyl acetate/petroleum ether).
In this manner the required compound XV or Synthon F was obtained in the form of a colourless oil.
Yield: 55% (from compound XII) aD= + 74" (chloroform, C = 1.4won) Elemental analysis C16 H20 03 Mol. Wt. : 260.333 calculated (%) C :73.81 H :7.74 found (%) C :73.81 H :7.71
M.S.
= = 260.
EXAMPLE 7
Preparation of 11 (R)-hydroxy- 13-oxa-prostanoic acid X=X1 =Z= H) a) 1(S)-form vlprop yleneacetal-2(R)-h ydroxy-3(R)-benzyloxy-cyclopentane (compound XVI in which D represents CH2 and R1 = phenyl)
In a three-necked flask maintained under nitrogen or argon atmosphere was dissolved 1.5 g of compound
XV obtained in Example 6 or Synthon F in 20 ml of freshly distilled tetrahydrofuran. After cooling to 0 C, 2 equivalents of a 1 M commercial solution of boron hydride in tetrahydrofuran were added. The medium was allowed to stand at 0 C and then for 15 minutes at room-temperature. After that, the reaction mixture was oxidized.For this purpose, the diborane in excess was destroyed at 0 C by adding, drop-by-drop, 1 ml of water, then 1.5 ml of a 3N-solution of sodium hydroxide and finally 3 ml of hydrogen peroxide. At the end of a 4-hour reaction-time, potassium carbonate was added. The mixture was diluted with ethyl ether and the ethereal phase was decanted out, washed with water, dried on sodium sulphate and evaporated under reduced pressure.
After separation by thin layer chromatography (solvent:1/2 ethyl acetate/petroleum ether) there were obtained 0.950 g of the required alcohol (one isomer) and 0.190 g of the starting product.
In this manner, the required compound XVI was provided.
Elemental analysis C16 H22 04 Mol. Wt. : 278.348 calculated (%) C :69.04 H :7.96 found (%) C :68.85 H :7.94 aD = + 5 (7.5 mg/ml) b) 1 (S)4ormylpropyleneacetal-2(R)-heptyloxy-3(R)-benzyloxy-cyclopentane (compound XXII in which Z' = H and R1 = phenyl)
Under nitrogen atmosphere and at 00C, 0.390 g of the required compound XVI previously obtained was added in 10 ml of N,N-dimethylformamide,to 0.600 g of an oily suspension of sodium hydride. Once the hydrogen evolution terminated, 0.7 ml of n-iodoheptane was added and the temperature was allowed to return to room-temperature. Two hours later, the reaction was complete and the mixture was cooled to 0 C and diluted with dichloromethane.The hydride in excess was destroyed by adding methanol and the solution was poured into iced water saturated with sodium chloride.
After extraction with dichloromethane, the organic phase was dried on sodium sulphate and then evaporated under reduced pressure. After separation by thin layer chromatography there was obtained 0.350 g of the required ether.
In this manner the required compound XXII was provided.
aD = + 5 (chloroform, C = 1 WN)
Elemental analysis C23 H36 04 Mol. Wt. : 376.537 calculated (%) C :73.26 H :9.63 found (%) C:73.18 H:9.62 Using the same procedure, 1 (S)-formylpropyleneacetal-2(R)-[2(S)-benzyloxy-heptyloxy]-3(R)-benzyloxy- cyclopentane was prepared.
Elemental analysis C29 H42 05 Mol. Wt. : 470.650 calculated (%) C : 74.00 H :8.99 found (%) C :73.96 H :8.95 c) 1(S)-form yl-2(R)-heptyloxy-3(R)-benzyloxy-cyclopentane (compound XXIII in which Z' = Hand R= phenyl) Under nitrogen atmosphere, 0.740 g of the required compound XXII previously obtained was dissolved in 5 ml of anhydrous chloroform. After that, 20 ml of 80%-formic acid were added and the reaction was monitored by thin layer chromatography (solvent : chloroform). After 24 hours, a further quantity of 10 ml of formic acid was added and the reaction was allowed to stand under nitrogen atmosphere for 24 hours.
The reaction medium was cooled and sodium bicarbonate was added. When the pH of the medium was 4, the solution was poured into iced water saturated with sodium chloride. This aqueous phase was taken up in dichloromethane. The organic phase was washed with an aqueous solution of sodium bicarbonate to neutrality and then with water. After drying on sodium sulphate and evaporation of the solvents in a coloured flask, 0.630 g of a clear yellow oil was obtained.
In this manner the required compound XXIII was provided.
I.R. spectrum : strip at 1705 cam~' M.S.
M+= 318 Using the same procedure, 1 (S)-formyl-2(R)-[2(S)-benzyloxy-heptyloxy]-3(R)-benzyloxy-cyclopentane was prepared.
MS.
M± = 424 d) 1 (S)-(6-carb oxy- 1-hexenyl)-2(R)-hep tyloxy-3(R)-benzyloxy-cyclopentane (compoundXXIVin which Z' = H and R, =phenyl)
To 0.940 g of sodium hydride were added 19.6 ml of freshly distilled dimethylsulphoxide and the mixture was heated to 700C for 1 hour. The solution of sodium methylsulphinyl methide, which became a greyish green colour, was then transferred to a three-necked flask containing 4.48 g of (5-carboxypentyl)triphenylphosphonium bromide maintained under argon atmosphere. The medium, which immediately turned red, was allowed to stand for one hour at room-temperature.
After that, 0.624 g of compound XXIII previously obtained dissolved under argon atmosphere in 19 ml of dimethylsulphoxide was added drop-by-drop to the ylide solution. The reaction medium was then allowed to stand for about 8 hours at room-temperature. The mixture was then poured into iced water containing a little sodium bicarbonate and the flask was rinsed with a 1/1 mixture of ethyl ether/petroleum ether. The aqueous phase was collected and then acidified to pH = 3 by adding oxalic acid. The aqueous phase was washed four times with ethyl ether and the ethereal phases were collected, dried on sodium sulphate and evaporated off under reduced pressure. The mixture so obtained was purified by chromatography on a column (eluent:1/1 ethyl acetate/petroleum ether).
In this manner, the required compound XXIV was obtained.
Yield: 33% aD = -45" (chloroform, C = 0.35 WN)
Elemental analysis
C26 H40 04 Mol. Wt. : 416.606 calculated (%) C :74.95 H :9.68 found (%) C:75.17 H:9.70
M.S.
M+ =416
Using the same procedure, 1 (S)-(6-carboxy-1 -hexenyl)-2(R)- [2(S)-benzyloxy- heptyloxyl3( R)-benzyl oxy- cyclopentane was prepared.
Elemental analysis C32 H46 0s Mol. Wt. : 510.715 calculated (%) C :75.25 H :9.07 found (%) C:75.19 H:9.0 M.S.
M+ = 510 e) 1 1(R)-Hydroxy- 13-oxa-prostanoic acid
Compound XXIV previously obtained was dissolved in a 1/1 mixture of acetic acid/ethanol in the presence of 10%-palladium charcoal. After a 48-hour period of hydrogenation in a Parr apparatus, the reaction medium was filtered on Whatmann paper and then chromatographed on a column.
In this manner 11 (R)-hydroxy-1 3-oxa-prostanoic acid was obtained.
Yield: 90% aD = + 19 (chlorofrom, C = 0.73 WN)
Elemental analysis
C19H3604 Mol. Wt. : 328.497 calculated (%) C :69.47 H: 11.04 found (%) C:69.54 H:10.97
M.S.
M+ = 328
Using the same procedure, 11 (R)-hydroxy-13-oxa-15(S)-hydroxy-prostanoic acid was prepared.
Elemental analysis
C19 H36 05 Mol. Wt. : 344.492 calculated (%) C :66.24 H:10.53 found (%) C:66.18 H:10.60
M.S.
M+ = 344
EXAMPLE 8
Preparation of 11(R)-hydroxy-13-oxa-prostanoic acid a) 2rSJ-formylpropyleneacetal-3gRJ-hydroxy-4FRJ-benzZloxy-cyclopentanone-ethylenedithioacetal rcom- pound XVI in which D represents
and R, = phenylJ In a 50 ml three-necked flask maintained under nitrogen atmosphere was dissolved 0.700 g of compound
IX obtained in Example 2 or Synthon B in about 5 ml of freshly distilled tetrahydrofuran. Using a syringe, 10 ml of a 1 M-commercial solution of boron hydride (BF3) in tetrahydrofuran was slowly added at 0 C under nitrogen. The reaction medium was allowed to stand for about 15 hours at room-temperature during which time a light current of nitrogen was passed through the flask. The borane that formed was then oxidized.For this purpose the hydride in excess was removed by slowly adding water (about 2 ml) at 0 C. Still at the same temperature, 2 ml of a 3N-solution of sodium hydroxide were added followed by 2 ml of 30%-hydrogen peroxide so as to oxidize the product. At the end of a 4-hour reaction-time, the reaction mixture was diluted with dichloromethane and poured into iced water saturated with ammonium chloride. The solution was taken up in dichloromethane and the organic phase was washed with water to neutrality, dried on sodium sulphate and evaporated off. The oil so obtained, which still contained some of the starting compound, was separated by thin layer chromatography and the product with the lower Rf value was collected (solvent:1/1 ethyl ether/petroleum ether).
In this manner, the required compound XVI was obtained in the form of a colourless oil.
Yield: 35% αD: -40" (CDCI3, C = 1.27% WN)
Elemental analysis C18H24S2 04 Mol. Wt. : 368.52 calculated (%) C: 58.66 H : 6.56 found (%) C: 58.99 H : 6.74 N.M.R. of the proton at250 MHz (CDCl3/TMS) 8(ppm) H
1.4 H80 2.1 Hga 2.37 H5a + H2
2.6 H5b
2.9 OH (disappeared after addition
of D20)
3.21 2Hg + 2Hg.
3.82 H70 + H7', 3.95 H3
5 H8 5.18 H7a + H7Sa 5.28 H4
5.6 CH2 (10)
7.35 phenyl 73C N.M. R. (CDCl3TMS)
N C 1 2 3 4 5 6 (ppm) 66.3 60.6 79 82.6 49.5 103.8 N'C 7 7' 8 9 9' 10 6 (ppm) 66.8 66.8 25.7 40.7 39.1 71.7
M.S.
M± = 368 b) 2rS)-formylpropyleneacetal-3FRJ-heptyloxy-4fRJ-benzZloxy-cyclopentanone-ethylenedithioacetal {com- pound XVIII in which Z' = H and R1 = phenyl)
Under nitrogen, a solution of 0.1 g of compound XVI previously obtained was added, in 5 ml of
N,N-dimethylformamide, to a suspension of 0.04 g of sodium hydride in 5 ml of N.N-dimethylformamide.
Once hydrogen evolution was terminated, 0.7 g of n-iodoheptane was introduced. The reaction was monitored by thin layer chromatography (solvent:1/1 ethyl ether/petroleum ether) and when this reaction terminated, the reaction medium was cooled to 0 C and diluted with 10 ml of dichloromethane. The hydride in excess was removed by adding methanol. The solution was poured into sodium chloride-saturated iced water and then taken up in methylene chloride. The organic phase was washed three times with water, dried on sodium sulphate and concentrated. The resulting oil was then separated by thin layer chromatography (solvent: 1/1 ethyl ether/petroleum ether).
In this manner, the required compound XVIII was obtained in the form of a colourless oil.
Yield: 60%
Elemental analysis
C25 H38 04 S2 Mol Wt. : 466.71 calculated (%) C: 64.34 H :8.20 S: 13.74 found (%) C:64.42 H:8.05 S:13.86 M.S.
= = 466 13C N. M. R. (CDCl3 TMS) N'C 1 2 3 4 5 6 7 7' 6 ppm) 67.8 58.6 84.5 84.1 48.2 102.7 66.3 66.5 N'C 8 9 9' 10 11 12 13 14 6 (ppm) 26 39 38.5 70.8 29.7 317 29 25.5
N C 15 16 17 6 (ppm) 22.5 13 71.6
N.M.R. of the proton at 250 MHz
6 (ppm) H
0.9 CH3(17)
1.27 CH2 (13-14-15-16)
1.55 CH2(12)+H8e 2.1 H8a 2.4 H2 + + 2Hs 3.2 2(Hg + Hg ) 3.5CH2(11)
3.8 H76 + H7, 4.1 H7a + H7'a, H3 H4
4.6 CH2 (10)
4.95 He (doublet) J(H6-H2) = 10 Hz
7.34 phenyl c) 1(S)formylpropyleneacetal-26RJ-heptyloxy-3fRJ-benzZloxy-cyclopentane (compound XXII in which Z' = H
and R1 = phenyl)
A solution of 0.1 g of compound XVIII previously obtained in ethanol was refluxed for about 15 hours in the presence of Raney nickel. After filtration on Celite the mixture was evaporated to dryness.
The 13 C N.M.R. and the proton N.M.R. spectra showed the presence of two products, one of which was unsaturated. The mixture was reduced, in the presence of Adams platinum and at atmospheric pressure, which led to one single compound.
In this manner, compound XVI was obtained.
Yield: 67% αD: + 5 (chloroform, C = 10 mg/ml)
M.S.
M+ = 376
Elemental analysis C23 H38 04 Mol. Wt. : 376.537 calculated (%) C : 73.36 H :9.63 found (%) C:73.18 H:9.62 73CN.M.R. {CDCl3(TMS)
N C 1 2 3 4 5 6 7
6 (ppm) 48.8 85.4 85 29.9 22.7 103.3 67
N C 7 8 9 10 11 12 13 6 (ppm) 67 25.8 69.7 29.9 31.8 29.2 26.1
N C 14 15 16 6 (ppm) 22.6 14.1 70.9
N.M.R. of the proton at250 MHz
6 (ppm) H
7.35 phenyl
4.55 benzyl
4.45 H6 (doublet) J (H6 - H2) = 6 Hz
4.15 H7e
3.75 H2, H3, H7a
3.80 multiplet O-CH2 (9) (chain)
2.05 H1 + H8a 1.7 2H1 + 2H8 + H80 (complex mass)
1.45 CH2(10)
1.3 CH2(11-12-13-14)
0.9 CH3(15) d) 1 (S)-formyl-2(R)-heptyloxy-3(R)-benzyloxy-cyclopentane (compound XXIII in which R , = phenyl)
In 4 ml of chloroform was dissolved 0.115 g of compound XXII previously obtained and then were added at 0 C 3 ml of a 50%-aqueous solution of trifluoroacetic acid. The reaction medium was then allowed to stand for 36 hours at room-temperature.After dichloromethane has been added, the reaction medium was neutralized with sodium bicarbonate, filtered and taken up in water. The aqueous phase was washed with dichloromethane, dried and evaporated. The mixture residue so obtained contained 50% of the desired aldehyde and a residue of 40% constituted by the starting product. The aldehyde was separated by thin layer chromatography (solvent: chloroform)
In this manner, compound XXIII was obtained.
M.S.
= = 318 (227,155,129,107, 318(227, 155, 129, 107,92, 91,83,67,65,57,55)
N. M. of the proton at 60 MHz Doublet of the aldehyde proton at 9.2 ppm e) 1 (S)-(6-carboxy- 1-hexen yl)-2(R)-hep tyloxy-3(R)-henzyloxy-cyclopentane (cornpound XXIV in which Z'=H) This compound was obtained in accordance with the method described in Example 7 d) above.
f) 1 1(R)-Hydroxy- 13-oxa -prostanoic acid
This compound was obtained in accordance with the method described in Example 7 e) above.
EXAMPLE 9
Preparation of9(S)-hydroxy- 11(R)- 13-oxa-prostanoic acid a) 1(S)-Benzyloxy-2-formylpropyleneacetal-4(R)-benzyloxy-2-cyclopentene (compound XXVlil in which
R, = phenyl)
To 0.187 g of sodium hydride were added 3 ml of N,N-dimethylformamide and the temperature was lowered to 0 C.
After that, 0.690 g of compound XI obtained in Example 4 or Synthon D, previously dissolved in 15 ml of
N,N-dimethylformamide, were introduced followed by 0.637 g (1.5 equivalent) of benzyl bromide under nitrogen atmosphere and at 0 C. The medium was allowed to stand for 3 hours and monitored by thin layer chromatography (solvent 3/1 chloroform/ethyl ether). At the end of this period of time, the reaction medium was cooled and the hydride in excess was removed by adding methanol.
The solution was poured drop-by-drop into iced water and then taken up with dichloromethane. The organic phase was dried on sodium sulphate, filtered and evaporated to dryness.
In this manner, the required compound XXVIII was obtained in the form of a colourless oil.
Yield: 90% aD= +46 (chloroform,C= 1.17WN)
Elemental analysis
C23 H26 04 Mol. Wt. : 366.461 calculated (%) C :75.38 H :7.15 found (%) C :75.35 H :7.18 M.S.
(M±-l)= 365 b) 1 (S)-Benzyloxy-2(S)-forrn ylprop yleneacetal-3(R)-hydroxy-4(R)-benzyloxy-cyclopentane (compound XXIX
in which R1 = phenyl)
The whole reaction was carried out under nitrogen atmosphere and the apparatus was previously dried at 1500C.
To 3.7 g of compound XXVIII previously obtained in 50 ml of freshly distilled tetrahydrofuran, was added drop-by-drop and at 0 C 1 equivalent of a 1 M commercial solution of boron hydride in tetrahydrofuran. After that, the reaction medium was allowed to stand at OOC for 2 hours and then overnight at room-temperature.
The hydride in excess was destroyed at 0 C by slowly adding the minimum quantity of water. Oxidation to alcohol was obtained by adding, at 00C, 2 ml of 6N sodium hydroxide and 1.8 ml of 30%-hydrogen peroxide.
The reaction was allowed to stand for 4 hours at room-temperature and the potassium carbonate was added.
The mixture was filtered and copiously rinsed with ethyl ether.
The ethereal phase so obtained was dried on sodium sulphate, filtered and evaporated to dryness. The alcohol so provided was crystallized from aqueous ethanol and the resulting mother liquors were separated out by chromatography on a column of silica gel (solvent:1/2 ethyl acetate/petroleum ether).
In this manner the required compound XXIX was obtained in a yield of 45%.
M.P.: 76-77"C (ethanol/water) aD = +48 (chloroform, C = 0.83 WN)
Elemental analysis C23 H28 05 Mol. Wt. : 384.477 calculated (%) C :71.85 H :7.34 found (%) C:71.86 H:7.33 c) 1 (S)-Benzyloxy-2(S)4orm ylprop yleneacetal-3(R)-heptyloxy-4(R)-benzyloxy-cyclopentane (compound XXV in which Z' = HandR1 =phenyl)
In a three-necked flask were placed 3 equivalents of an oily suspension of sodium hydride under nitrogen atmosphere. After washing with dry hexane, 5 ml of N,N-dimethylformamide were added. The temperature was lowered to 0 C and then 1 g of compound XXIX previously obtained dissolved in 15 ml of
N,N-dimethylformamide, was added.
Once hydrogen evolution terminated, 1.4 ml of n-iodoheptane (Mol Wt. 229, d = 1.37) was added. After about 8 hours at room-temperature, the reaction medium was cooled to 0 C, diluted with dichloromethane and the hydride in excess was removed by adding methanol. The solution was then poured into iced water saturated with sodium chloride taken up with dichloromethane and dried on sodium sulphate. After evaporation to dryness, the desired product so obtained was purified by chromatography on a silica gel column (solvent: 1/2 ethyl acetate/petroleum ether).
In this manner the required compound XXV was obtained in the form of a colourless oil.
Yield: 75%
Elemental analysis C3D H42 05 Mol. Wt. : 482.66 calculated (%) C : 74.65 H :8.77 found (%) C : 74.59 H : 8.82 a0 = 0 (chloroform, C = 1.7 WN)
Using the same procedure, 1 (S)-benzyloxy-2(S)-formylpropyleneacetal-3(R)-[2(S)-benzyloxy-heptyloxy]- 4(R)-benzyloxy-cyclopentane was prepared.
Elemental analysis C36 H48 O6 Mol. Wt. : 576.774 calculated (%) C :74.96 H :8.38 found (%) C :74.89 H : 8.40 d) 1 (S)-Benzyloxy-2 (8)-form yI-3(R)-heptyloxy-4(R)-benzyloxy-cyclopentane (compound XXX in which Z' = H and R = phenyl) Under argon atmosphere, 1.5 ml of a 80%-aqueous solution of formic acid was added to 0.085 g (0.176 m mol) of compound XXV previously obtained. After about 8 hours at room-temperature, the reaction mixture was diluted with dry dichloromethane and sodium bicarbonate was added to obtain a pH of about 4. The solution was taken up with anhydrous chloroform, washed with water to neutral pH, dried on sodium sulphate, filtered and evaporated to dryness.
In this manner, 0.063 9 of the required compound XXX was obtained in the form of an oil which eventually turned yellow.
Yield: 90% I.R. spectrum : CHO at 1720 cam~' Elemental analysis C27 H36 04 Mol. Wt. : 424.581 calculated (%) C :76.38 H :8.54 found (%) C :75.98 H : 8.49 Using the same procedure, 1 (S)-benzyloxy-2(S)-formyl-3(R)-[2(S)-benzyloxy-heptyloxyl-4(R)-benzyloxy- cyclopentane was obtained.
Elemental analysis C34 H42 05 Mol. Wt : 530.705 calculated (%) C :76.94 H :7.97 found (%) C :77.0 H : 8.01 e) 1(S)-BenzZloxy-2(S)-(6-carboxy-1-hexenylJ-3(R)-heptyloxy-4FR)-benzZloxy-cyclopentanercompoundXXXI in whichZ' = Hand RZ = phenyl)
This compound was obtained in accordance with the method described in Example 7 d) above.
Elemental analysis 039 H46 05 Mol. Wt : 522.726 calculated (%) C :75.82 H :8.87 found (%) C :75.60 H : 8.91 Using the same procedure, 1 (S)-benzyloxy-2(S)-(6-carboxy-1 -hexenyl)-3(R)-[2(S)-benzyloxy-heptyloxy]- 4(R)-benzyloxy-cylopentane was provided.
Elemental analysis C40 H52 06 Mol. Wt. : 628.85 calculated (%) C :76.39 H :8.35 found (%) C :76.10 H : 8.39 f) 9(S)-Hydroxy- 1 1(R)-hydroxy- 13-oxa-prostanoic acid
This compound was obtained in accordance with the method described in Example 7e above.
Elemental analysis C19 H36 05 Mol. Wt. : 344.492 calculated (%) C :66.24 H :10.53 found (%) C:65.95 H:10.80 M.S.
M+ =344 Using the same procedure, 9(S)-hydroxy-11(R)-hydroxy-13-oxa-15(S)-hydroxy-prostanoic acid was obtained.
Elemental analysis C19 H36 0s Mol. Wt. : 360.491 calculated (%) C :63.30 H:10.06 found (%) C: 63.33 H: 9.85
M.S.
M± = 360
Claims (19)
1. Prostanoic acid derivatives represented by the general formula:
in which X represents hydrogen or hydroxy, X1 represents hydrogen or X and X1, when they are taken together with the carbon atoms to which they are attached, represent a carbonyl group and Z represents hydrogen or hydroxy, and pharmaceutically acceptable alkali metal salts thereof.
2. 11 (R)-Hydroxy-13-oxa-prostanoic acid and pharmaceutically acceptable alkali metal salts thereof.
3. 11 (R)-Hydroxy-13-oxa-15(S)-hydroxy-prostanoic acid and pharmaceutically acceptable alkali metal salts thereof.
4. 9(S)-Hydroxy-1 1 (R)-hydroxy-13-oxa-prostanoic acid and pharmaceutically acceptable alkali metal salts thereof.
5. 9(S)-Hydroxy-11 1(R)-hydroxy-1 (R)-hydroxy-13-oxa-15(S)-hydroxy-prostanoic acid and pharmaceutically acceptable alkali metal salts thereof.
6. A process for preparing a prostanoic acid derivative as claimed in Claim 1, wherein a compound of the general formula:
in which R represent a hvdroxv-Drotectina arouP of the formula -CH2R( in which R1 represents an aryl or aralkyl radical, D' represents a radical
and Z' represents hydrogen or a radical O-R, R having the same meaning as given above for both radicals, is hydrogenolysed on platinum charcoal or palladium charcoal at room-temperature and in an appropriate medium to obtain: either the required 13-oxa-prostaglandin in free acid form in which X represents hydrogen or hydroxy or a (6-carboxyhexenyl )-3(R)-heptyloxy derivative of the general formula:
in which Z has the same meaning as given above, which is dethioacetalised with mercuric chloride in an appropriate solvent and in the presence of boron trifluoride etherate to provide the required 13-oxaprostaglandin in free acid form in which X and X1, when they are taken together with the carbon atom to which they are attached represent a carbonyl group, the free acid so obtained being further reacted, if desired, with an appropriate alkali metal hydroxide to obtain a pharmaceutically acceptable alkali metal salt thereof.
7. Process according to Claim 6, wherein the medium is an acetic acid/ethanol medium and the solvent is acetone.
8. Process according to Claim 6, wherein the aryl radical is phenyl substituted or not by a methyl radical and the aralkyl radical is benzyl substituted or not in the aromatic moiety by a methyl radical.
9. A pharmaceutical or veterinary composition comprising as an essential active ingredient at least one prostanoic acid derivative according to any one of Claims 1 to 5, in association with a pharmaceutical carrier or excipient therefor.
10. A method of provoking bronchodilation or inducing inhibition of blood-platelet aggregation in a host needing such treatment which method comprises administering to said host an effective amount of at least one compound according to any one of Claims 1 to 5.
11. Cyclopentene derivatives represented by the general formula:
in which R represents a hydroxy-protecting group of the formula -CH2R1 in which R1 represents an aryl or aralkyl radical, B represents
and A is such that: - when B represents
represents
- when B represents
A represents
12. Cyclopentene derivatives according to Claim 11, wherein the aryl radical is phenyl substituted or not by a methyl radical and the aralkyl radical is benzyl substituted or not in the aromatic moiety by a methyl radical.
13. Process for preparing a cyclopentene derivative according to Claim 11,wherein 11,wherein:
a) an hexanedial derivative of general formula:
in which R has the same meaning as given above and D represents
or
is cyclised under inert atmosphere with pyrrolidine acetate or piperidine acetate in an appropriate solvent and at a temperature ranging from - 1 00C to room-temperature to provide the required cyclopentene derivative in which:B represents
and A represents
b) the cyclopentene derivative obtained under a) above is treated with 1 ,3-propanediol at a temperature between room-temperature and 40"C and in the presence of p-toluenesulphonic acid, the treatment being carried out in an anhydrous solvent to provide the required cyclopentene derivative in which B represents
and A represents
c) the cyclopentene derivative obtained under b) above in which A represents
is treated with neutral diphenylselenic anhydride at room-temperature and in an appropriate solvent to provide the required cyclopentene derivative in which B represents
and A represents
d) the cyclopentene derivative obtained under c) above is treated with diisobutyl aluminium hydride in an appropriate anhydrous solvent and at a temprature ranging from -10 C to room-temperature to provide the required cycopentene derivative in which B represents
and A represents
14. Process according to Claim 13, wherein in a, band d, the solvent is benzene or toluene, and in c the solvent is dichloromethane.
15. Process according to Claim 13, in which A represents
and B represents
the compound obtained being Synthon B.
16. Process according to Claim 13, in which A represents
and B represents
(Synthon D).
17. Process according to Claim 13, in which A represents
and B represents
(Synthon F).
18. Method for the preparation of a derivative of Claim 1, wherein a cyclopentane derivative of general formula:
in which R represents a hydroxy-protecting group of the formula -CH2R1 in which R1 represents an aryl or aralkyl radical, Z' represents hydrogen or a radical -OR and E represents
having the same meaning as given above for both radicals, is submitted to the following reactions:
a) hydrolysis of the formylpropyleneacetal group in an acid medium to obtain an aldehyde group;
b) treatment of the aldehyde group with the dianion of (5-carboxypentyl)-triphenylphosphonium bromide in accordance with the conditions of the Wittig reaction to fix an ethylene carbon chain ; and
c) hydrogenolysis on platinum charcoal or palladium charcoal to saturate the ethylenic chain and deprotect the hydroxyl groups followed, when necessary, by dethioacetalisation with mercuric chloride to form a keto group, so as to obtain the required compound according to Claim 1, the compound of formula XXXIII being itself obtained as follows:
A) - treatment of Synthons B or F with boron hydride followed by oxidation of the borane formed to fix a hydroxyl group on the ethylenic bond;
- reaction with a n-halogenoheptane derivative to etherifythe hydroxyl group so formed and optionally:
either: reduction of the ethylenedithioacetal group with Raney nickel
or : dethioacetalisation with mercuric chloride to form a ketone group, reduction with lithium
tri-sec-butylborohydride to form a hydroxyl group and protection of the hydroxyl group so as to form the compound of formula XXXIII;
B) - protection of the free hydroxyl group of Synthon D;
- treatment of the O-protected derivative obtained with boron hydride and subsequent oxidation of the
borane so formed to fix a hydroxyl group on the ethylenic bond ; and
- reaction with a n-halogenoheptane derivative to etherify the hydroxyl group so formed so as to obtain the compound of formula XXXIII in which E represents
19. Process for preparing a prostanoic acid derivative as claimed in Claim 1, substantially as described in any one of the foregoing Examples 7,8 and 9.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX958281U MX6835E (en) | 1981-08-11 | 1981-07-30 | PROCEDURE FOR PREPARING CYCLOPENTENE DERIVATIVES |
GB8124488A GB2082176B (en) | 1980-08-12 | 1981-08-11 | Heteroprostaglandin derivatives and processes for preparing them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8026240 | 1980-08-12 | ||
GB8124488A GB2082176B (en) | 1980-08-12 | 1981-08-11 | Heteroprostaglandin derivatives and processes for preparing them |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2082176A true GB2082176A (en) | 1982-03-03 |
GB2082176B GB2082176B (en) | 1984-07-11 |
Family
ID=26276528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8124488A Expired GB2082176B (en) | 1980-08-12 | 1981-08-11 | Heteroprostaglandin derivatives and processes for preparing them |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2082176B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0160495A2 (en) * | 1984-04-24 | 1985-11-06 | Glaxo Group Limited | Cyclopentyl ethers and their preparation and pharmaceutical formulation |
FR2580632A1 (en) * | 1985-04-23 | 1986-10-24 | Glaxo Group Ltd | CYCLOPENTILIC ETHERS, THEIR PHARMACEUTICAL PREPARATION AND FORMULATION CONTAINING THEM |
-
1981
- 1981-08-11 GB GB8124488A patent/GB2082176B/en not_active Expired
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0160495A2 (en) * | 1984-04-24 | 1985-11-06 | Glaxo Group Limited | Cyclopentyl ethers and their preparation and pharmaceutical formulation |
EP0160495A3 (en) * | 1984-04-24 | 1986-08-27 | Glaxo Group Ltd | Cyclopentyl ethers and their preparation and pharmaceutical formulation |
FR2580632A1 (en) * | 1985-04-23 | 1986-10-24 | Glaxo Group Ltd | CYCLOPENTILIC ETHERS, THEIR PHARMACEUTICAL PREPARATION AND FORMULATION CONTAINING THEM |
Also Published As
Publication number | Publication date |
---|---|
GB2082176B (en) | 1984-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aristoff et al. | Total synthesis of a novel antiulcer agent via a modification of the intramolecular Wadsworth-Emmons-Wittig reaction | |
US5459160A (en) | Iridoid derivatives and the use thereof as a drug | |
JP4312594B2 (en) | Novel bicyclic and tricyclic cannabinoids | |
WO1999008987A1 (en) | Cyclohexenone long-chain alcohol and medicament containing same | |
GB2133405A (en) | Dibenzo (bd)pyran derivatives and their preparation and pharmaceuticala formulations | |
FR2553774A1 (en) | INTERPHENYLENE ANALOGUES OF 7-OXABICYCLOHEPTANE SUBSTITUTED PROSTAGLANDINS, IN PARTICULAR USEFUL AS CARDIOVASCULAR AGENTS | |
EP0051917A1 (en) | Benzofuran ethanolamine derivatives, processes for their preparation, and their use in medicine | |
US20030069212A1 (en) | Synthesis of A-ring synthon of 19-nor-1alpha, 25-dihydroxyvitamin D3 from (D)-glucose | |
US5200536A (en) | Fluorine-containing vitamin D3 analogues | |
US4377704A (en) | Hetero-prostaglandin derivatives and processes for preparing them | |
Marshall et al. | Total synthesis of (+-)-4-deoxydamsin. Structure correlation of pseudoguaianolide sesquiterpenes | |
US4088779A (en) | 9-Oxaprostaglandins | |
GB2082176A (en) | Heteroprostaglandin derivatives and processes for preparing them | |
JPS61129145A (en) | Manufacture of hydroquinone derivative | |
US4024181A (en) | Analogues of prostanoic acids | |
US3736336A (en) | 4,5-disubstituted-2,3-epoxycyclo-pentanones | |
CA1194021A (en) | Heteroprostaglandin derivatives and processes for preparing them | |
Cantrell | Reactivity of photochemically excited 3-acylthiophenes, 3-acylfurans, and the formylthiophenes and furans | |
US4958037A (en) | Precursors and synthesis of methyl-9-oxo-11α, 16-dihydroxy-16-vinyl-5-cis-13-trans-prostadienoates | |
US5434300A (en) | Method for preparing dodecahydro-3A,6,6,9A-tetramethylnaphtho [2,1-B]furan and novel haloethyl decalin derivatives | |
CA1180339A (en) | Chiral compounds useful for the preparation of hetero prostaglandin derivatives | |
US4012396A (en) | Processes and intermediates for cis or trans 2-or 3-(1-acyl-3-vinyl-4-piperidine)acetic or propionic acid esters | |
NO157100B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTIC ACTIVITIES (3,2,0) -BICYCLOHEPTANOXIMETERS AND THEIR NON-TOXIC SALTS. | |
US4296121A (en) | Novel prostaglandin derivatives of the Δ2-PGF2 and Δ2-PGE2 series and process for their manufacture | |
US4985571A (en) | 6-membered lactones useful as intermediates for antilipemic mevalonic acid lactones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |